News

Guselkumab, which was subcutaneously injected in the participating patients, was assessed for its efficacy and safety in the DISCOVER 1 and 2 trials compared to placebo. Janssen said

The program is intended to assist drug supply chain stakeholders, including FDA, in developing the electronic, interoperable system that will identify and trace certain prescription drugs as they

Previously known as COR-001, ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD).

The FDA has approved Kanjinti for all approved indications of the reference product Herceptin to treat HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal

Patients who achieved low disease activity (LDA) with XELJANZ (tofacitinib) extended release (XR) 11 mg once daily (QD) plus methotrexate (MTX) after a 24-week open-label run-in period, were

PhoreMost has identified and validated the target using its next-generation SITESEEKER phenotypic screening technology. Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors

The acquisition of Medidata will help Dassault to create its first end-to-end scientific and business platform for life sciences industry. As per terms of the deal, Dassault will

The regulator has approved Keytruda as monotherapy and also in combination with a commonly used chemotherapy regimen – platinum and fluorouracil (FU). The approval is for first-line treatment

This brings together the expertise of Professor Alessio Ciulli, one of the pioneers in the field of Proteolysis targeting chimeras (PROTACs), based in the School of Life Sciences